Stifel Nicolaus Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $4.00

X4 Pharmaceuticals (NASDAQ:XFOR) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

X4 Pharmaceuticals Trading Down 1.6 %

NASDAQ:XFOR opened at $0.40 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.04 and a current ratio of 6.07. The company has a market capitalization of $67.99 million, a P/E ratio of -4.42 and a beta of 0.39. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The stock’s 50 day moving average price is $0.59 and its 200 day moving average price is $0.75.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million for the quarter. On average, research analysts forecast that X4 Pharmaceuticals will post -0.65 EPS for the current fiscal year.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, COO Mary Dibiase sold 67,695 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the sale, the chief operating officer now directly owns 452,060 shares in the company, valued at $257,674.20. This represents a 13.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Adam S. Mostafa sold 230,645 shares of X4 Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $126,854.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 580,800 shares of company stock valued at $321,447. 1.62% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. State Street Corp increased its holdings in X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in shares of X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after buying an additional 111,032 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of X4 Pharmaceuticals by 15.1% in the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after buying an additional 81,968 shares during the last quarter. GSA Capital Partners LLP bought a new stake in X4 Pharmaceuticals during the 3rd quarter worth about $340,000. Finally, K2 Principal Fund L.P. acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at about $284,000. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.